The present invention provides compounds represented by formula 1:
wherein, R
1
R
2
, R
3
, R
4
, R
5
, R
6
, R
7
, R
8
, R
9
, R
10
, R
11
, R
12
, R
13
and X are as defined in the specification, in all its stereoisomeric and tautomeric forms and mixtures thereof in all ratios, and its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable polymorphs and prodrugs. These compounds are useful for treatment of inflammatory disorders including those caused by elevated levels of proinflammatory cytokines such as Tumor Necrosis Factor (TNF-α and/or interleukins (IL-1β, IL-6, IL-8). The invention also relates to processes for the manufacture of compounds of formula 1 and pharmaceutical compositions containing them.
本发明提供了由式1所表示的化合物,其中,R1R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13和X在规范中定义,包括其所有立体异构体和互变异构体以及在所有比例中的混合物,以及其药学上可接受的盐、药学上可接受的溶剂化合物、药学上可接受的多晶形和前药。这些化合物可用于治疗炎症性疾病,包括由前炎症细胞因子如肿瘤坏死因子(TNF-α)和/或白细胞介素(IL-1β、IL-6、IL-8)
水平升高引起的疾病。本发明还涉及制备式1化合物的方法和含有它们的制药组合物。